These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23959396)

  • 1. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
    Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
    Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
    Han SW; Cha Y; Paquet A; Huang W; Weidler J; Lie Y; Sherwood T; Bates M; Haddad M; Park IH; Oh DY; Lee KS; Im SA; Bang YJ; Ro J; Kim TY
    PLoS One; 2012; 7(7):e39943. PubMed ID: 22848366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
    Montemurro F; Prat A; Rossi V; Valabrega G; Sperinde J; Peraldo-Neia C; Donadio M; Galván P; Sapino A; Aglietta M; Baselga J; Scaltriti M
    Mol Oncol; 2014 Feb; 8(1):20-6. PubMed ID: 24075779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
    Duchnowska R; Sperinde J; Chenna A; Haddad M; Paquet A; Lie Y; Weidler JM; Huang W; Winslow J; Jankowski T; Czartoryska-Arłukowicz B; Wysocki PJ; Foszczyńska-Kłoda M; Radecka B; Litwiniuk MM; Zok J; Wiśniewski M; Zuziak D; Biernat W; Jassem J
    Clin Cancer Res; 2014 May; 20(10):2805-13. PubMed ID: 24668646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
    Sperinde J; Huang W; Vehtari A; Chenna A; Kellokumpu-Lehtinen PL; Winslow J; Bono P; Lie YS; Petropoulos CJ; Weidler J; Joensuu H
    Clin Cancer Res; 2018 Jul; 24(13):3046-3052. PubMed ID: 29535130
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
    Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
    Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.
    Green AR; Barros FF; Abdel-Fatah TM; Moseley P; Nolan CC; Durham AC; Rakha EA; Chan S; Ellis IO
    Breast Cancer Res Treat; 2014 May; 145(1):33-44. PubMed ID: 24706169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P95 HER2 fragments and breast cancer outcome.
    Tural D; Akar E; Mutlu H; Kilickap S
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
    Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
    [No Abstract]   [Full Text] [Related]  

  • 13. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
    Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
    Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
    J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of p95HER2 in trastuzumab resistance in breast cancer.
    Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
    J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.
    Bates M; Sperinde J; Köstler WJ; Ali SM; Leitzel K; Fuchs EM; Paquet A; Lie Y; Sherwood T; Horvat R; Singer CF; Winslow J; Weidler JM; Huang W; Lipton A
    Ann Oncol; 2011 Sep; 22(9):2014-2020. PubMed ID: 21289364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.
    Weitsman G; Barber PR; Nguyen LK; Lawler K; Patel G; Woodman N; Kelleher MT; Pinder SE; Rowley M; Ellis PA; Purushotham AD; Coolen AC; Kholodenko BN; Vojnovic B; Gillett C; Ng T
    Oncotarget; 2016 Aug; 7(32):51012-51026. PubMed ID: 27618787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
    Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients.
    Maria AM; El-Shebiney M; El-Saka AM; Zamzam Y
    J Egypt Natl Canc Inst; 2018 Jun; 30(2):49-55. PubMed ID: 29779938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.
    Desmedt C; Sperinde J; Piette F; Huang W; Jin X; Tan Y; Durbecq V; Larsimont D; Giuliani R; Chappey C; Buyse M; Winslow J; Piccart M; Sotiriou C; Petropoulos C; Bates M
    Diagn Mol Pathol; 2009 Mar; 18(1):22-9. PubMed ID: 19214112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.